Aridis Pharmaceuticals, Inc.

ARDS · OTC
Analyze with AI
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Activities
Net Income-$30,371-$42,193-$22,333-$29,681
Dep. & Amort.$487$435$337$338
Deferred Tax$0-$722$0$0
Stock-Based Comp.$1,479$2,251$2,128$2,010
Change in WC-$1,299$10,517-$617$18,223
Other Non-Cash$577$6,776$9$951
Operating Cash Flow-$29,127-$22,936-$20,476-$8,159
Investing Activities
PP&E Inv.-$82-$530-$367-$174
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$82-$530-$367-$174
Financing Activities
Debt Repay.$3,200$5,000$715$0
Stock Issued$12,609$29,715$7,949$4,958
Stock Repurch.$0$0$0$0
Dividends Paid$0-$4,127$0$0
Other Fin. Act.-$1,027$4,132$14$35
Financing Cash Flow$14,782$34,720$8,678$4,993
Forex Effect$0$0$0$0
Net Chg. in Cash-$14,427$11,254-$12,165-$3,340
Supplemental Information
Beg. Cash$19,986$8,732$20,897$24,237
End Cash$5,559$19,986$8,732$20,897
Free Cash Flow-$29,209-$23,466-$20,843-$8,333
Aridis Pharmaceuticals, Inc. (ARDS) Financial Statements & Key Stats | AlphaPilot